{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:57:43Z","timestamp":1776704263126,"version":"3.51.2"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.retram.2020.05.005","type":"journal-article","created":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T16:35:50Z","timestamp":1597509350000},"page":"159-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-4271","authenticated-orcid":false,"given":"Farah","family":"Yassine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemant","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.retram.2020.05.005_bib0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.retram.2020.05.005_bib0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"issue":"23","key":"10.1016\/j.retram.2020.05.005_bib0015","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.retram.2020.05.005_bib0020","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"10230","key":"10.1016\/j.retram.2020.05.005_bib0025","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.retram.2020.05.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085554","article-title":"Survival of adults with acute lymphoblastic leukemia in Germany and the United States","volume":"9","author":"Pulte","year":"2014","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.retram.2020.05.005_bib0035","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.retram.2020.05.005_bib0040","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.retram.2020.05.005_bib0045","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.retram.2020.05.005_bib0050","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.retram.2020.05.005_bib0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.retram.2020.05.005_bib0060","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.retram.2020.05.005_bib0065","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0070","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2019-125792","article-title":"A comparison of two-year outcomes in ZUMA-1 (Axicabtagene ciloleucel) and SCHOLAR-1 in patients with refractory large B cell lymphoma","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.retram.2020.05.005_bib0075","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.retram.2020.05.005_bib0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2020.05.005_bib0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","article-title":"Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2020.05.005_bib0090","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood-2018-99-117199","article-title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.retram.2020.05.005_bib0095","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.243246","article-title":"Impact and safety of chimeric antigen receptor T cell therapy in older, vulnerable patients with relapsed\/refractory large b-cell lymphoma","author":"Lin","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.retram.2020.05.005_bib0100","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41375-019-0476-y","article-title":"Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/refractory B cell non-Hodgkin lymphoma","volume":"33","author":"Jain","year":"2019","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0105","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2019-130983","article-title":"Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-cell therapy for adults with Diffuse Large B-Cell Lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) registry","volume":"134","author":"Jaglowski","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0110","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2019-129097","article-title":"Experience with axicabtagene ciloleucel (Axi-cel) in patients with secondary CNS involvement: results from the US lymphoma CAR T consortium","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.retram.2020.05.005_bib0115","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-019-0437-5","article-title":"Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL","volume":"33","author":"He","year":"2019","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.retram.2020.05.005_bib0120","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.retram.2020.05.005_bib0125","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.retram.2020.05.005_bib0130","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","article-title":"A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients","volume":"56","author":"Salvi","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0135","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/blood-2019-124694","article-title":"Comorbidities predict inferior survival in patients receiving CAR T-cell therapy for relapsed\/refractory DLBCL: a multicenter retrospective analysis","volume":"134","author":"Kittai","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.retram.2020.05.005_bib0140","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.retram.2020.05.005_bib0145","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood Adv"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2019-129624","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0155","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2019-131482","article-title":"Use of bendamustine for lymphodepletion before tisagenlecleucel (anti-CD19 CAR t cells) for aggressive B-cell lymphomas","volume":"134","author":"Svoboda","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0160","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2019-124750","article-title":"Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.retram.2020.05.005_bib0165","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.bbmt.2018.12.311","article-title":"Cytopenias after chimeric antigen receptor T-cells (CAR-T) infusion; patterns and outcomes","volume":"25","author":"Shaefer","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0170","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1182\/blood-2019-127087","article-title":"Outcomes and factors impacting use of axicabtagene ciloleucel in refractory and relapsed large B-cell lymphoma: an intent-to-treat analysis","volume":"134","author":"Mian","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0175","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2019-127490","article-title":"A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for Relapsed\/Refractory aggressive B-cell lymphomas","volume":"134","author":"Riedell","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0180","doi-asserted-by":"crossref","first-page":"767-","DOI":"10.1182\/blood-2019-124177","article-title":"Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in England","volume":"134","author":"Kuhnl","year":"2019","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.retram.2020.05.005_bib0185","doi-asserted-by":"crossref","first-page":"301-","DOI":"10.1002\/hon.110_2630","article-title":"Real-world results on cd19 car T-cell for 60 French patients with relapsed\/refractory diffuse large B-cell lymphoma included in a temporary authorization for use program","volume":"37","author":"Thieblemont","year":"2019","journal-title":"Hematol Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0190","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2019-131078","article-title":"Outcomes in aggressive B-cell non-hodgkin lymphomas with anti-CD19 CAR T-Cell (CTL019) products not meeting commercial release specifications","volume":"134","author":"Chong","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0195","doi-asserted-by":"crossref","first-page":"4108-","DOI":"10.1182\/blood-2019-131399","article-title":"A characterization of bridging therapies leading up to commercial CAR T-cell therapy","volume":"134","author":"Dwivedy Nasta","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.retram.2020.05.005_bib0200","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2020.05.005_bib0205","doi-asserted-by":"crossref","first-page":"4220-","DOI":"10.1182\/blood-2018-99-117133","article-title":"Radiation therapy as a bridging strategy for refractory diffuse large B cell lymphoma patients awaiting CAR T manufacturing of axicabtagene ciloleucel","volume":"132","author":"Jain","year":"2018","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0210","doi-asserted-by":"crossref","first-page":"1609-","DOI":"10.1182\/blood-2019-131499","article-title":"Radiation therapy can be an effective bridging strategy prior to axicabtagene ciloleucel therapy for relapsed\/refractory large B-cell lymphoma","volume":"134","author":"Pinnix","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.retram.2020.05.005_bib0215","doi-asserted-by":"crossref","first-page":"2619-","DOI":"10.1182\/blood-2019-129279","volume":"134","author":"Grupp","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2020.05.005_bib0220","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.retram.2020.05.005_bib0225","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.retram.2020.05.005_bib0230","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2020.05.005_bib0235","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"224","key":"10.1016\/j.retram.2020.05.005_bib0240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.retram.2020.05.005_bib0245","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.20","article-title":"Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit\u2019 ALL\u2019","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.retram.2020.05.005_bib0250","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.retram.2020.05.005_bib0255","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.retram.2020.05.005_bib0260","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.retram.2020.05.005_bib0265","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1016\/j.clml.2019.07.190","volume":"19","author":"Pasquini","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.retram.2020.05.005_bib0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-020-0850-4","article-title":"Patient-reported outcomes in acute graft-versus-host disease: optimizing patient care and clinical trial endpoints","author":"Patel","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.retram.2020.05.005_bib0275","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.retram.2020.05.005_bib0280","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2020.05.005_bib0285","doi-asserted-by":"crossref","first-page":"2289-","DOI":"10.1182\/blood-2018-99-111711","article-title":"Patient-reported and neurocognitive outcomes in patients treated with axicabtagene ciloleucel","volume":"132","author":"Jim HSL","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.retram.2020.05.005_bib0290","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.6594","article-title":"Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT)","author":"Sidana","year":"2019","journal-title":"American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.retram.2020.05.005_bib0295","doi-asserted-by":"crossref","first-page":"21","DOI":"10.21037\/cco.2018.04.02","article-title":"Chimeric antigen receptor T cells, a savior with a high price","volume":"7","author":"de Lima Lopes","year":"2018","journal-title":"Chin Clin Oncol"},{"issue":"19","key":"10.1016\/j.retram.2020.05.005_bib0300","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"FDA approval of tisagenlecleucel: promise and complexities of a $475000 cancer drug","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.retram.2020.05.005_bib0305","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.retram.2020.05.005_bib0310","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nbt0518-375","article-title":"Allogene and Celularity move CAR-T therapy off the shelf","volume":"36","author":"Sheridan","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.retram.2020.05.005_bib0315","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nbt0518-375","article-title":"Allogene and Celularity move CAR-T therapy off the shelf","volume":"36","author":"Sheridan","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.retram.2020.05.005_bib0320","article-title":"CAR T-Cell therapies in the EU5: what can we expect from payers?","author":"Privolnev","year":"2019","journal-title":"Cell Gene"},{"issue":"10","key":"10.1016\/j.retram.2020.05.005_bib0325","doi-asserted-by":"crossref","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"issue":"24","key":"10.1016\/j.retram.2020.05.005_bib0330","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.retram.2020.05.005_bib0335","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.retram.2020.05.005_bib0340","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamapediatrics.2018.2530","article-title":"Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia","volume":"172","author":"Whittington","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.retram.2020.05.005_bib0345","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia","author":"Sarkar","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.retram.2020.05.005_bib0350","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/hum.2017.254","article-title":"CAR T cells in trials: recent achievements and challenges that remain in the production of modified t cells for clinical applications","volume":"29","author":"Kohl","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.retram.2020.05.005_bib0355","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.retram.2020.05.005_bib0360","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2019Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.retram.2020.05.005_bib0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.12.011","article-title":"Organoid-induced differentiation of conventional t cells from human pluripotent stem cells","volume":"24","author":"Montel-Hagen","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"21","key":"10.1016\/j.retram.2020.05.005_bib0370","doi-asserted-by":"crossref","first-page":"1116-","DOI":"10.1182\/blood.V124.21.1116.1116","article-title":"Allogenic T-cells targeting CD123 for adoptive immunotherapy of acute myeloid leukemia (AML)","volume":"124","author":"Galetto","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.retram.2020.05.005_bib0375","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/annonc\/mdz285","article-title":"Development of adaptive immune effector therapies in solid tumors","volume":"30","author":"Comoli","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.retram.2020.05.005_bib0380","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.retram.2020.05.005_bib0385","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12015-019-09901-7","article-title":"Solid tumors challenges and new insights of car t cell engineering","volume":"15","author":"Tahmasebi","year":"2019","journal-title":"Stem Cell Rev Rep"},{"issue":"5","key":"10.1016\/j.retram.2020.05.005_bib0390","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40259-019-00368-z","article-title":"Chimeric antigen receptor-T cells for targeting solid tumors: current challenges and existing strategies","volume":"33","author":"Springuel","year":"2019","journal-title":"BioDrugs"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318620300386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318620300386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:38:39Z","timestamp":1762821519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318620300386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2452318620300386"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2020.05.005","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2020.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}